Injection site reactions after Tdap immunization were reported in 26 ( 78.8 % [ 95 % CI , 61.1 % -91.0 % ] ) and 12 ( 80 % [ 95 % CI , 51.9 % -95.7 % ] ) pregnant and postpartum women , respectively ( P > .99 ) .